News Conference News TVT 2022 No Stroke Reduction With Embolic Protection in TAVI, Two Studies Suggest Michael O'Riordan June 09, 2022
News Daily News Subclinical Thrombosis After TAVI Benign, at Least to 3 Years Michael O'Riordan June 07, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for May 2022 Shelley Wood June 01, 2022
News Conference News EuroPCR 2022 Self-Expanding TAVI Valves Offer Best Results in Small Failed Aortic Bioprostheses: LYTEN Caitlin E. Cox May 27, 2022
News Conference News EuroPCR 2022 Next-Generation Navitor Valve Shows Promise in High-risk TAVI Patients Yael L. Maxwell May 27, 2022
News Conference News EuroPCR 2022 Thrombotic vs Bleeding Risks Post-TAVI: Insights From GALILEO Yael L. Maxwell May 23, 2022
News Conference News EuroPCR 2022 Better Durability With Self-Expanding TAVI? Clues From UK TAVI Shelley Wood May 18, 2022
News Conference News EuroPCR 2022 JenaValve Trilogy Meets the Challenge of AR in Early Real-World Use Caitlin E. Cox May 18, 2022
News Conference News EuroPCR 2022 Changes in Cardiac Damage After AVR Tied to 2-Year Outcomes Caitlin E. Cox May 17, 2022
News Opinion Editor's Corner EuroPCR 2022 EuroPCR Kicks Off In Person Next Week in Paris: Here’s What to Expect Shelley Wood May 12, 2022
News Daily News NCDR Analyses Offer Insights Into First-Generation Watchman Outcomes L.A. McKeown May 03, 2022
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for April 2022 Shelley Wood May 02, 2022
News Daily News The NCDR Has Made a Difference, but Experts See Room for Growth Todd Neale April 28, 2022
News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
News Conference News ACC 2022 Self-Expanding TAVI Looks More Durable Than SAVR at 5 Years Michael O'Riordan April 04, 2022
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Daily News Surgical Societies Question VARC-3 Endpoints for Valve Disease Trials Michael O'Riordan March 23, 2022